RA drug access program offers continued treatment for prior study participants
NCT ID NCT03559686
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program provides ongoing access to certolizumab pegol (Cimzia) for adults with rheumatoid arthritis who took part in earlier open-label studies. Participants receive the standard maintenance dose of 200 mg every two weeks. The goal is to allow continued disease management or a smooth transition to standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- certolizumab pegol (Cimzia)
- What this could lead to
- If successful, this program could help maintain disease control in people with rheumatoid arthritis who have already benefited from the drug.
- What could go wrong
- This is not a new trial but a continuation program for a limited group. It does not test new benefits or safety, and results may not apply to the wider RA population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can group learning make biotherapy safer for arthritis patients?
- Can a specialized hand exercise protocol restore grip and ease pain in rheumatoid arthritis?